Standout Papers
- The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. (1993)
- Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer (2007)
- The Patient-Reported Outcomes Measurement Information System (PROMIS) (2007)
- Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer (2003)
- Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes (2007)
- Item Banks for Measuring Emotional Distress From the Patient-Reported Outcomes Measurement Information System (PROMIS®): Depression, Anxiety, and Anger (2011)
- Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system (1997)
- Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument. (1997)
- Development of physical and mental health summary scores from the patient-reported outcomes measurement information system (PROMIS) global items (2009)
- Measuring spiritual well-being in people with cancer: The functional assessment of chronic illness therapy—spiritual well-being scale (FACIT-Sp) (2002)
- Psychometric Evaluation and Calibration of Health-Related Quality of Life Item Banks (2007)
- The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation. (2003)
- Impact of Cancer-Related Fatigue on the Lives of Patients: New Findings From the Fatigue Coalition (2000)
- Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial (2005)
- Development of a PROMIS item bank to measure pain interference (2010)
- Combining Anchor and Distribution-Based Methods to Derive Minimal Clinically Important Differences on the Functional Assessment of Cancer Therapy (FACT) Anemia and Fatigue Scales (2002)
- Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer (2007)
- Fatigue in cancer patients compared with fatigue in the general United States population (2002)
- A case for including spirituality in quality of life measurement in oncology (1999)
- Reliability and validity of the functional assessment of cancer therapy—lung (FACT-L) quality of life instrument (1995)
- Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. (1997)
- Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. (1998)
- Gemcitabine Alone Versus Gemcitabine Plus Radiotherapy in Patients With Locally Advanced Pancreatic Cancer: An Eastern Cooperative Oncology Group Trial (2011)
- Measuring financial toxicity as a clinically relevant patient‐reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST) (2016)
- The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. (1997)
- A Comprehensive Method for the Translation and Cross-Cultural Validation of Health Status Questionnaires (2005)
- Minimally important differences were estimated for six Patient-Reported Outcomes Measurement Information System-Cancer scales in advanced-stage cancer patients (2011)
- Phase III Trial of Four Cisplatin-Containing Doublet Combinations in Stage IVB, Recurrent, or Persistent Cervical Carcinoma: A Gynecologic Oncology Group Study (2009)
- The development of a financial toxicity patient‐reported outcome in cancer: The COST measure (2014)
- PROMIS® Adult Health Profiles: Efficient Short-Form Measures of Seven Health Domains (2019)
- PROMIS®-29 v2.0 profile physical and mental health summary scores (2018)
- Establishing a common metric for depressive symptoms: Linking the BDI-II, CES-D, and PHQ-9 to PROMIS Depression. (2014)
- Clinical validity of PROMIS Depression, Anxiety, and Anger across diverse clinical samples (2016)
- PROMIS measures of pain, fatigue, negative affect, physical function, and social function demonstrated clinical validity across a range of chronic conditions (2016)
- Minimal important change (MIC): a conceptual clarification and systematic review of MIC estimates of PROMIS measures (2021)
Immediate Impact
8 from Science/Nature 138 standout
Citing Papers
Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis
2021 Standout
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer
2021 Standout
Works of David Cella being referenced
Phase III Trial of Four Cisplatin-Containing Doublet Combinations in Stage IVB, Recurrent, or Persistent Cervical Carcinoma: A Gynecologic Oncology Group Study
2009 Standout
Phase III Study of Cisplatin With or Without Paclitaxel in Stage IVB, Recurrent, or Persistent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study
2004
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| David Cella | 36142 | 18003 | 8579 | 14947 | 1.2k | 91.6k | |
| Graham A. Colditz | 32864 | 11054 | 3000 | 9036 | 1.4k | 162.0k | |
| Neil K. Aaronson | 17199 | 9304 | 4554 | 6442 | 457 | 45.9k | |
| Stuart Pocock | 9393 | 16133 | 8313 | 6721 | 569 | 137.2k | |
| Jan P. Vandenbroucke | 8818 | 12248 | 5045 | 7200 | 439 | 107.2k | |
| Gordon Guyatt | 9155 | 28738 | 16319 | 9036 | 1.3k | 166.8k | |
| Henrik Toft Sørensen | 8401 | 9272 | 2446 | 6708 | 1.6k | 75.0k | |
| Jonathan J Deeks | 7918 | 11118 | 2813 | 5438 | 346 | 90.3k | |
| Andrew D Oxman | 6183 | 11315 | 10554 | 7316 | 282 | 102.0k | |
| Holger J. Schünemann | 5335 | 11004 | 8513 | 4545 | 693 | 82.6k | |
| M. Hassan Murad | 6081 | 15504 | 2424 | 5369 | 955 | 98.8k |
All Works
Login with ORCID to disown or claim papers
Loading papers...